Summary by Futu AI
EyePoint Pharmaceuticals officer, DAVID S JONES, is set to sell 38,541 shares of common stock on 01/22/2024, as per the latest filing. The shares, valued at an aggregate market value of $860,235.12, were acquired on the same day through the exercise of stock options directly from the issuer. The transaction involved a cash payment made for the securities. This sale follows a period where no other securities transactions were reported by JONES in the past three months, according to the provided review of securities sold.